Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iKids-Growth is a nutritional supplement developed by GeneScience Pharmaceuticals (GenSci) designed to support height development in children with growth-related conditions. The product is part of GenSci's iKids pediatric health portfolio and is primarily formulated with gamma-aminobutyric acid (GABA). GABA is included for its purported ability to stimulate the endogenous secretion of growth hormone from the pituitary gland by acting as a neurotransmitter that modulates the hypothalamic-pituitary-somatotropic axis. iKids-Growth is currently being evaluated in clinical trials in China for various growth-related indications, including children with low preadolescent insulin-like growth factor 1 (IGF-1) levels and short stature homeobox-containing (SHOX) gene deficiency. In these studies, it is often investigated as a non-hormonal intervention, either as a standalone treatment or in comparison with recombinant human growth hormone (rhGH) therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iKids-Growth.